article thumbnail

Samsung Biologics, GreenLight conclude Covid-19 vaccine engineering run

Pharmaceutical Technology

Samsung Biologics and GreenLight Biosciences have completed the initial commercial-scale engineering run for their messenger ribonucleic acid (mRNA) Covid-19 vaccine under their manufacturing collaboration. The post Samsung Biologics, GreenLight conclude Covid-19 vaccine engineering run appeared first on Pharmaceutical Technology.

Engineer 262
article thumbnail

World’s first engineered B cell therapy enters human trials

Drug Discovery World

The first patient has been dosed with an engineered B cell investigational therapy in a Phase I trial in Mucopolysaccharidosis type I (MPS I). Immusoft is advancing the world’s first engineered B cell therapy, which may have significant impact for patients with this rare disease and potentially many others.

Engineer 113
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How single-use technologies can improve antibodies production  

Drug Discovery World

However, despite these advancements in process optimisation and cell culture engineering, there remain areas that we need to improve. DC: Antibodies have and remain a large product class within the biopharmaceutical market. RA: How can anion exchange (AEX) chromatographic approaches improve production processes for antibodies?

article thumbnail

CIGB-128 by Center for Genetic Engineering and Biotechnology for Brain Tumor: Likelihood of Approval

Pharmaceutical Technology

CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. According to GlobalData, Phase I drugs for Brain Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase I.

article thumbnail

CIGB-128 by Center for Genetic Engineering and Biotechnology for Brain Tumor: Likelihood of Approval

Pharmaceutical Technology

CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. According to GlobalData, Phase I drugs for Brain Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase I.

article thumbnail

Engineering A Healthier Future: The Power of Tissue Regeneration

Roots Analysis

The Art and Science of Tissue Engineering Do you know that scientists are now able to grow body parts in the lab? This incredible medical breakthrough is called tissue engineering. So, what is tissue engineering? Having said that regenerative grafts created using tissue engineering have numerous applications.

article thumbnail

Bristol Myers Squibb to take over US plant for cell therapy production   

Pharmaceutical Technology

Bristol Myers Squibb will take over a former Novartis plant to boost viral vector production for chimeric antigen receptor (CAR) T-cell therapies. Bristol Myers Squibb stated that the facility will provide viral vector production capabilities for its two CAR T-cell therapies. This process is both operationally and technically complex.